02552 HUA MEDICINE-B
- 1.560
- -0.050-3.11%
HUA MEDICINE-B News
華領醫藥-B：年報 2023
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Hualing Pharmaceutical-B (02552.HK) held a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18 | Hualing Pharmaceutical-B (02552.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, and the proposed final dividend (if any), and other matters.
HUA MEDICINE-B: Date of Board Meeting
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552) rose more than 6%. Second-generation GKA submitted an IND application to the US FDA, Huatangning's sales volume can be expected
Hualing Pharmaceutical-B (02552) rose more than 6%. As of press release, it rose 6.19% to HK$2.4, with a turnover of HK$6.734,900.
Home Linjiang: Hong Kong stocks in 2024, or the continuation of the structured market...
The Hang Seng Healthcare Index has generally produced good companies over the past few years, and they deserve a lot of attention from investors in 2024.
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US
Hua Medicine (HKG:2552) has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for permission to conduct trials of the firm's second generation anti-dia
Hualing Pharmaceutical-B (02552) submitted a new drug clinical trial application for a second-generation glucokinase ectopic activator to the FDA and was accepted
Jinwu Financial News | Hualing Pharmaceutical-B (02552) announced that the company has submitted a new drug clinical trial (IND) application to the US Food and Drug Administration for a second-generation glucokinase ectopic activator (second-generation GKA) to initiate a phase I randomized, double-blind, placebo-controlled, single-dose, safety, tolerability, pharmacokinetics and pharmacodynamics study for type 2 diabetes (T2D) subjects in the US. This IND application is the first step in the company's strategy to expand its innovative approach to “repair sensors, restore homeostasis, and treat diabetes at source” to regions outside of mainland China, and its first generation
Dogliatetin was successfully selected into the medical insurance catalogue, and commercialization of Hualing Pharmaceutical-B (2552.HK) accelerated
The annual health insurance negotiations came to an end, and a new list was finally released at the end of the year. Judging from the results, in addition to the regular customers that appear every year, fresh blood has also joined this time, including the world's first innovative drug, Huatangning (doglietine tablets) independently developed by Hualing Pharmaceutical. It is worth noting that behind this new FIC drug, which has brought breakthrough treatment plans to many diabetics, Hualing Pharmaceutical's stock price has also shown a recovery trend recently, driven by favorable news such as Bayer's 800 million milestone payment and expected inclusion in health insurance. So, what are the signals behind this new health insurance adjustment worth paying attention to? Hualing Pharmaceutical Enters
Changes in Hong Kong stocks | Pharmaceutical stocks rebounded strongly, innovative drugs accelerated entry into health insurance, global biomedical investment and financing data recovered slightly
Pharmaceutical stocks rebounded strongly in early trading, with CRO leading the way. As of press release, Zaiding Pharmaceutical (09688) rose 7.78% to HK$23.55; Kanglong Chemical (03759) rose 6.44% to HK$15.54; and Pharmaceuticals Biotech (02269) rose 5.89% to HK$29.65.
The commercialization process is speeding up again! Hualing Pharmaceutical-B (02552)'s self-developed innovative drug doglietine will be covered by medical insurance
On December 13, Hualing Pharmaceutical-B (02552) announced that the world's first innovative drug for diabetes, glucokinase activator (GKA), dogliatetin (Huatangning), which was independently developed by the company, was successfully included in the national medical insurance drug catalogue.
Hualing Pharmaceutical announced that dogliadetine has been included in the national medical insurance drug catalogue
Shanghai, December 13, 2023/PRNewswire/ -- Hualing Pharmaceutical (the “Company”, Hong Kong Stock Exchange stock code: 2552.HK) announced today that the company's self-developed diabetes drug glucokinase activator (GKA) doglietine (trade name: Huadangning) has been successfully included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue” (“National Health Insurance”) published by the National Health Insurance Administration (“National Health Insurance Administration”). Dogliatetin is Hualing Pharmaceutical's first commercialized product to participate in health insurance negotiations for the first time. The successful entry into health insurance this time marks Hualing
The new medical insurance catalogue was announced, and Hualing Pharmaceutical's world-first new drug for diabetes, doglietine, was successfully selected
On December 13, Hualing Pharmaceutical-B (02552) announced that the company's first commercialized product, GKA dogliatetin (Huatangning), the company's first commercialized product and the world's first innovative drug for diabetes, has been included in the national medical insurance drug catalogue. This is also the first time that Hualing Pharmaceutical has participated in health insurance negotiations. According to the medical insurance drug catalogue, the price of dogliadine is 5.39 yuan/tablet, and the daily medication price is 10.78 yuan. This price exceeds the current maximum price of oral hypoglycemic drugs in the medical insurance catalogue by 46%. The results of the 2023 national health insurance negotiations were announced today. A total of 126 new drugs were selected. It is expected to be official on January 1, 2024
Is Hua Medicine (Shanghai) (HKG:2552) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552) rose more than 7% in the intraday period, the market size of oral diabetes drugs continued to expand, and the company's sales of dogliadine tablets were impressive
Hualing Pharmaceutical-B (02552) rose more than 7% in the intraday period, and the stock has accumulated nearly 40% in the past month. As of press release, it increased 4.17% to HK$2.25, with a turnover of HK$2,106,900.
Hualing Pharmaceutical-B (02552.HK): Hualing Shanghai received a milestone payment of 800 million yuan from Bayer relating to the achievement of an important milestone in Huatangning's development
Gelonghui November 22丨Hualing Pharmaceutical-B (02552.HK) announcement, which relates to (among others) the commercial cooperation agreement between Hualing Pharmaceutical Technology (Shanghai) Co., Ltd. (“Hualing Shanghai”), a wholly-owned subsidiary of the company, and Bayer Healthcare Co., Ltd. to commercialize dorzagliatin (a type of diabetes treatment) in China and establish a strategic partnership in this regard; (ii) the content (including) the listing of a new drug application for Huatangning (dogleitin tablets, dorzagliatin, HMS5552) Approval; (iii) the content includes
Changes in Hong Kong stocks | Innovative drug concepts continue to rise, pioneering pharmaceutical-B (09939) rises more than 15%, institutions say health insurance negotiations are getting warmer
The concept of innovative drugs continued to rise in early trading. As of press release, Pioneer Pharmaceutical-B (09939) rose 15.25% to HK$3.4; Hualing Pharmaceutical-B (02552) rose 9.04% to HK$2.05; Connoah-B (02162) rose 5.25% to HK$56.1; and Tengsheng Pharmaceutical-B (02137) rose 3.77% to HK$2.75.
Changes in Hong Kong stocks | Hualing Pharmaceutical (02552) rose more than 10%, and the company brought important varieties of dogliadine tablets to conduct 2023 national health insurance negotiations
Hualing Pharmaceutical (02552) rose more than 10%, up 10.11% at press time to HK$2.07, with a turnover of HK$5.38 million.
Changes in Hong Kong stocks | Innovative drug concepts buck the market and rise, national health insurance negotiations officially begin, agencies say price cuts may be less than expected
The concept of innovative drugs bucked the market. As of press release, Hualing Pharmaceutical-B (02552) rose 12.28% to HK$1.92; Connoah-B (02162) rose 7.96% to HK$54.25; Genting Xinyao B (01952) rose 6.8% to HK$27.5; and Cinda Biotech (01801) rose 2.99% to HK$44.8.
Analysis
Price Target
No Data
